Loading...
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
Aim: The selective BRAF and MEK inhibitors (BRAFi+MEKi) have substantially improved the survival of melanoma patients with BRAF V600 mutations. However, BRAFi+MEKi can also cause severe or fatal outcomes. We aimed to identify and compare serious adverse events (sAEs) that are significantly associate...
Na minha lista:
| Udgivet i: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7352287/ https://ncbi.nlm.nih.gov/pubmed/32580351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12061650 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|